Evidence map›Paper›PMID 39386634›Full record

ArticlebioRxiv : the preprint server for biology2024

A unique interplay of access and selection shapes peritoneal metastasis evolution in colorectal cancer.

Emma Ce Wassenaar, Alexander N Gorelick, Wei-Ting Hung, David M Cheek, Emre Kucukkose, I-Hsiu Lee, Martin Blohmer, Sebastian Degner, Peter Giunta, Rene Mj Wiezer and 14 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Emma Ce WassenaarDepartment of Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands.ORCID 0000-0002-7525-9135
Alexander N GorelickDepartment of Genetics, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6736-8246
Wei-Ting HungCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8533-9972
David M CheekDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Emre KucukkoseDepartment of Surgical Oncology, Laboratory Translational Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
I-Hsiu LeeDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Martin BlohmerDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Sebastian DegnerDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Peter GiuntaDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Rene Mj WiezerDepartment of Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands.
Mihaela G RaicuDepartment of Pathology, St. Antonius Hospital, Nieuwegein, the Netherlands.
Inge UbinkDepartment of Surgical Oncology, Laboratory Translational Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
Sjoerd J KlaasenOncode Institute, Hubrecht Institute-KNAW (Royal Academy of Arts and Sciences) and University Medical Centre Utrecht, Utrecht, the Netherlands.
Nico LansuOncode Institute, Hubrecht Institute-KNAW (Royal Academy of Arts and Sciences) and University Medical Centre Utrecht, Utrecht, the Netherlands.
Emma V WatsonUniversity of Massachusetts Medical School, Worcester, MA, USA.
Ryan B CorcoranDivision of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Genevieve BolandDivision of Surgical Oncology, Department of Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Gad GetzKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Geert Jpl KopsOncode Institute, Hubrecht Institute-KNAW (Royal Academy of Arts and Sciences) and University Medical Centre Utrecht, Utrecht, the Netherlands.
Dejan JuricKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-3555-5295
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Djamila BoermaDepartment of Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands.
Onno KranenburgDepartment of Surgical Oncology, Laboratory Translational Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0002-2112-4390
Kamila NaxerovaDepartment of Genetics, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7744-5110

Funding

Illuminating the evolutionary history of colorectal cancer metastasis: basic principles and clinical applicationsR37CA225655 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAXEROVA, KAMILA · 2018 to 2024
$3.0M
Defining the role of seed and soil in peritoneal metastasis evolutionR01CA279054 · NCI · HARVARD MEDICAL SCHOOL · PI Kamila Naxerova · 2024 to 2026
$2.0M
NCI NIH HHS R01 CA279054NCI NIH HHS R37 CA225655
6 · The paper itself

Abstract

Whether metastasis in humans can be accomplished by most primary tumor cells or requires the evolution of a specialized trait remains an open question. To evaluate whether metastases are founded by non-random subsets of primary tumor lineages requires extensive, difficult-to-implement sampling. We have realized an unusually dense multi-region sampling scheme in a cohort of 26 colorectal cancer patients with peritoneal metastases, reconstructing the evolutionary history of on average 28.8 tissue samples per patient with a microsatellite-based fingerprinting assay. To assess metastatic randomness, we evaluate inter- and intra-metastatic heterogeneity relative to the primary tumor and find that peritoneal metastases are more heterogeneous than liver metastases but less diverse than locoregional metastases. Metachronous peritoneal metastases exposed to systemic chemotherapy show significantly higher inter-lesion diversity than synchronous, untreated metastases. Projection of peritoneal metastasis origins onto a spatial map of the primary tumor reveals that they often originate at the deep-invading edge, in contrast to liver and lymph node metastases which exhibit no such preference. Furthermore, peritoneal metastases typically do not share a common subclonal origin with distant metastases in more remote organs. Synthesizing these insights into an evolutionary portrait of peritoneal metastases, we conclude that the peritoneal-metastatic process imposes milder selective pressures onto disseminating cancer cells than the liver-metastatic process. Peritoneal metastases' unique evolutionary features have potential implications for staging and treatment.

Identifiers

PMID39386634
PMCPMC11463674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.